Longitudinal Association of Statin Treatment With Insulin Sensitivity and Beta-Cell Function in the PROMISE Cohort
Authors' conclusion
Statin treatment was associated with lowered insulin sensitivity and beta-cell function with potential differential effects among statin agents and the sexes.
Study context
- Population
- Adults at risk for T2D, PROMISE cohort; aged 50 years, 74% female
- Participants
- 498 adults
- Exposure
- Statin use vs no statin treatment
- Statin usersn = 169
- Outcome
- Longitudinal changes in insulin sensitivity (insulin sensitivity index, HOMA for insulin sensitivity) and beta-cell function (insulinogenic index/HOMA-IR, insulin secretion sensitivity index-2)
- Follow-up
- Baseline and 3 visits over 9 years
Methodological detailslongitudinal, 9-year follow-up, generalized estimating equations, Statin use self-reported
- Longitudinal
- 9-year follow-up
- Generalized estimating equations
- Statin use self-reported
Main finding
As reported in the abstract
over 9 years
Lower insulin sensitivity
5.32%-6.36%
P < 0.001
Statin users
Lower beta-cell function
4.93%-7.59%
P < 0.001
Statin users
Observational data: associations, not effects.
Further findings
By statin agent
- Rosuvastatin associated with decreased insulin sensitivity and beta-cell function
- Atorvastatin showed moderate inverse association with beta-cell function and insulin sensitivity
By sex
- In females, statins reduced insulin sensitivity and beta-cell function
- In males, only beta-cell function was altered
Original publication
Longitudinal Association of Statin Treatment With Insulin Sensitivity and Beta-Cell Function in the PROMISE Cohort. J Clin Endocrinol Metab. Published 17 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →